EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, ENDRA Life Sciences's Enterprise Value is $1.17 Mil.
ENDRA Life Sciences's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was $-9.58 Mil. Therefore, ENDRA Life Sciences's EV-to-FCF for today is -0.12.
The historical rank and industry rank for ENDRA Life Sciences's EV-to-FCF or its related term are showing as below:
NDRA'
s EV-to-FCF Range Over the Past 10 Years
Min: -4.85 Med: -0.02 Max: 0.83
Current: -0.12
During the past 10 years, the highest EV-to-FCF of ENDRA Life Sciences was 0.83. The lowest was -4.85. And the median was -0.02.
NDRA's EV-to-FCF is ranked worse than 100% of 104
companies
in the Medical Diagnostics & Research industry
Industry Median: 27.875
vs NDRA: -0.12
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The historical data trend for ENDRA Life Sciences's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of ENDRA Life Sciences's EV-to-FCF
For the Diagnostics & Research subindustry, ENDRA Life Sciences's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ENDRA Life Sciences's EV-to-FCF Distribution in the Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, ENDRA Life Sciences's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where ENDRA Life Sciences's EV-to-FCF falls into.
ENDRA Life Sciences's current Enterprise Value is $1.17 Mil.
ENDRA Life Sciences's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-9.58 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ENDRA Life Sciences (NAS:NDRA) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
ENDRA Life Sciences's PE Ratio for today is calculated as:
ENDRA Life Sciences's share price for today is $0.3267.
ENDRA Life Sciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.810.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
ENDRA Life Sciences EV-to-FCF Related Terms
Thank you for viewing the detailed overview of ENDRA Life Sciences's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
ENDRA Life Sciences (ENDRA Life Sciences) Business Description
ENDRA Life Sciences Inc is engaged in the development of Thermo Acoustic Enhanced UltraSound (TAEUS) to visualize tissue like MRI but at 1/50th the cost and at the point of patient care. TAEUS is designed to work in concert with around 400,000 cart-based ultrasound systems in use globally today. TAEUS is initially focused on the measurement of fat in the liver as a means to assess and monitor Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH), chronic liver conditions that affect over one billion people globally, and for which there are no practical diagnostic tools. Beyond the liver, the firm is exploring several other clinical applications of TAEUS, including visualization of tissue temperature during energy-based surgical procedures.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
NDRA has been successfully added to your 